NeoRx's radiotherapy proves safe in high doses:
This article was originally published in Clinica
Executive Summary
NeoRx plans to treat bone cancer patients with the highest doses of its Skeletal Targeted Radiotherapy (STR) product in a Phase III trial, following positive results from a Phase I study. Even at the highest doses of STR, multiple myeloma patients showed no significant side effects, according to the Seattle, Washington-based company, which has nearly completed a Phase II trial. The product, a drug that delivers the radionuclide holmium-166 to bone, could provide an intensive and effective treatment for older patients and its may also potentially be used to treat other diseases such as prostate cancer, said NeoRx.